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Lipophilic statins induce apoptosis of human vascular smooth (VSMC) in the intima is the final result of migration
muscle cells. from the media, proliferation, and eventual death of
Background. The accumulation of vascular smooth muscle VSMC [7, 8]. Statins have been reported to inhibitcells (VSMC) in the intima is an early feature of atherosclerosis
VSMC migration [9] and proliferation [9–11]. However,that results from a balance of migration from the media, prolif-
little attention has been paid to the potential effect oferation, an eventual death (including programmed cell death)
of VSMC. Several reports have described that HMG-CoA re- statins on VSMC apoptosis, in spite of the fact that a
ductase inhibitors (statins) attenuate both the migration and defective apoptosis may play a relevant role in the devel-
proliferation of VSMC. However, the potential effect of statins opment of atherosclerotic lesions [8, 12, 13]. We haveon VSMC programmed cell death has received little attention.
recently reported that lipophilic statins promote apopto-Methods. Human and rat VSMC were incubated with differ-
sis of rat VSMC in culture [14]. In this report, we extendent concentration of statins in the presence of fetal bovine
serum as a survival factor. The presence of apoptosis was evalu- this finding to human VSMC. Our data suggest that pro-
ated by morphological criteria, flow cytometry and DNA elec- tein prenylation inhibition by statins may play a role in
trophoresis. VSMC apoptosis, providing an additional mechanism byResults. Lipophilic statins induced, in a dose-dependent
which HMG-CoA reductase inhibitors may modify themanner the appearance of VSMC apoptosis. The effect of
pathophysiology of atherosclerosis.statins was fully reversed by mevalonate, farnesylpyrophos-
phate, and geranylgeranypyrophosphate, but not by cholesterol
or other mevalonate metabolites, suggesting a role for isopren-
METHODSoids in VSMC apoptosis. In addition, the induction of apoptosis
by statins was associated with the inhibition of prenylation of Dulbecco’s modified Eagle’s minimum media (DMEM),
Rho B.
penicillin, streptomycin, and trypsin-EDTA were fromConclusions. The present results suggest that protein prenyl-
Bio Whitaker (Walkersville, MD, USA). Fetal bovineation inhibition by statins may be involved in statin-induced
VSMC apoptosis. These data provide a new potential mecha- serum (FBS) was from Gibco (Gaithersburg, MD, USA).
nism by which statins may modulate the evolution of athero- Atorvastatin and pravastatin were obtained from Parke
sclerotic lesions. Davis (Ann Arbor, MI, USA) and Bristol Myers-Squibb
Spain (Madrid, Spain). Lovastatin and simvastatin (from
Merck Sharp and Dohme Spain, Madrid, Spain) were
3-Hydroxy-3-methylglutaryl co-enzyme A (HMG- converted to the active compounds as described by Kita,
CoA) reductase inhibitors (statins) have been shown to Brown and Goldstein [15]. The remaining reagents were
attenuate neointimal thickening in experimental models obtained from Sigma unless specified otherwise.
of atherosclerosis by mechanisms independent of lipid Vascular smooth muscle cells were isolated and culti-
reduction [1–3]. Increasing data suggest that some of the vated as previously described [14]. Human VSMC were
remarkable beneficial effects in humans may also involve a kind Gift of Dr. C. Caramelo (Fundacio´n Jime´nez
mechanisms not mediated by cholesterol reduction [4–6]. Dı´az, Madrid, Spain). Cells were characterized as smooth
The accumulation of vascular smooth muscle cells muscle cells by their typical hill-and-valley morphology
by contrast-phase microscopy and by positive immuno-
staining for a-smooth muscle actin (clone 1 A4; Sigma).Key words: cell death, HMG-CoA reductase inhibitors, mevalonate,
protein isoprenylation, atherosclerosis. Media were replaced every two to three days. At conflu-
ence, cells were harvested for passaging with trypsin- 1999 by the International Society of Nephrology
S-88
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Fig. 1. Lipophilic statins induce rat and human vascular smooth muscle cell (VSMC) apoptosis. Exponentially growing rat (lower left panel) and
human (lower right panel) VSMC were exposed to increasing concentrations of different statins. The presence of apoptosis was evaluated as the
proportion of cells exhibiting a hypodiploid DNA content as assessed by flow cytometry (A0, arrows, upper panel). As shown, VSMC treatment
with lipophilic statins (namely atorvastatin, simvastatin, lovastatin, h), but not with the hydrophilic pravastatin was associated with the appearance
of cells with a hypodiploid DNA content, indicative of apoptosis; this effect was fully reversed by mevalonate ( ). Symbol (j) is control.
EDTA. Cells between passages 3 to 12 were used for all polyclonal antibody (Sc – 180; Santa Cruz Biotechnol-
ogy) as described [14].the experiments.
Cellular DNA content was assessed by flow cytometry Representative data from two to four independent
experiments will be presented. For quantitative data, theas previously described [14]. Briefly, cells from different
experimental conditions were collected with trypsin-2.2 mean 6 sd of triplicate or quadruplicate samples from
one out of three to five independent experiments willmmol/liter EDTA in PBS, mixed with detached cells
present in the supernatant, and resuspended in a solution be presented. For the comparison of group means the
one way analysis of variance and the Student-Newman-containing 75 mmol/liter propidium iodide, 10 mg/ml
RNAse A, 0.05% Nonidet P-40 in PBS. Then they were Keuls tests were used as appropriate. A P-value ,0.05
was considered as statistically significant.incubated at 48C for 30 minutes in the dark and analyzed
by flow cytometry (Coulter EPICSt XL-MCL flow cyto-
meter, Hialeah, FL, USA) using LYSIS II software.
RESULTS AND DISCUSSION
For the evaluation of DNA fragmentation, 10 million
Lipophilic HMG-CoA reductase inhibitors inducecells were incubated under the different experimental
apoptosis of VSMCconditions for 48 hours and soluble DNA was resolved
in a 1.5% agarose gel containing ethidium bromide as To evaluate whether HMG-CoA reductase inhibitors
induce apoptosis of VSMC, exponentially growing sub-previously described [14]. Gels were examined and pho-
tographed under ultraviolet light. confluent VSMC were exposed to increasing concentra-
tions of different HMG-CoA reductase inhibitors in theTo assess the degree of Rho B prenylation, the disap-
pearance of Rho B from the membrane fractions and its presence of 10% FBS as a survival factor. Treatment
with lipophilic statins (atorvastatin, simvastatin, lova-appearance in the cytosolic fractions was used. Rat
VSMC were incubated for 24 hours with different statins statin) was associated with cell rounding, detachment
from the plate substrate and surrounding cells, and theand equal amounts of protein from membrane or soluble
fractions were immunoblotted with rabbit anti-Rho B appearance of chromatin condensation and fragmenta-
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Fig. 2. Effect of statins and isoprenoids on
DNA fragmentation and Rho B prenylation.
Rat vascular smooth muscle cells (VSMC) were
exposed to the indicated statins (100 mmol/
liter for all of them) in the presence of 100
mmol/liter mevalonate (MVA), 5 mmol/liter
farnesyl-pyrophosphate (FPP), or 5 mmol/liter
geranylgeranyl-pyrophosphate (GGPP). The
effects on DNA fragmentation (laddering, A)
and on Rho B prenylation (as assessed by
its membrane association, B) were evaluated
after 48 and 24 hours of incubation, respec-
tively. Lipophilic statins, but not pravastatin,
inhibited the prenylation of Rho B, induced
its appearance in the cytosolic fraction, and
promoted DNA fragmentation. All these ef-
fects were reversed by either mevalonate or
its metabolites FPP and GGPP. Adapted from
Reference [14], with permission from the pub-
lisher.
tion, characteristic of apoptosis (not shown). In addition, this regard, pravastatin, as compared to other statins,
was less efficacious in reducing vascular injury in twothese changes were associated with the appearance of a
cell population with a reduced DNA content (hypodip- experimental models of atherosclerosis [3, 16]. Whether
the potential benefits of a direct action of lipophilic stat-loid) usually referred to as sub G1 or A0, as assessed by
flow cytometry, characteristic of apoptosis (Fig. 1). Quite ins on the vascular wall may be overshadowed by an
increased incidence of extrahepatic side effects is at pres-similar results were obtained with human and VSMC,
although a longer period of incubation (72 vs. 24 hr) was ent unknown.
We next evaluated which among the mevalonaterequired to clearly detect the pro-apoptotic effect of
statins in human cells (Fig. 1). metabolites might be involved in statin-induced apop-
tosis [18, 19]. Isopentenyl adenine, ubiquinone (coen-In contrast, treatment of either rat or human VSMC
with the hydrophilic drug pravastatin, up to 100 mmol/ zyme Q10), squalene or cholesterol (present in the
serum-supplemented media) failed to reverse the statin-liter, failed to induce any significant degree of apoptosis
induced effects (not shown). In contrast, the isoprenoidsabove the basal levels. The reduction in cellular DNA
farnesyl- pyrophosphate (FPP) and geranylgeranyl-pyro-content by lipophilic statins, was paralleled by the ap-
phosphate (GGPP) fully reversed the proapoptotic ef-pearance of DNA fragmentation into multiples of 180
fects of lipophilic statins (Figs. 1 and 2).to 200 kb, constituting a typical laddering pattern charac-
teristic of apoptosis (Fig. 2). As expected, mevalonate
HMG-CoA reductase inhibition andfully reversed the pro-apoptotic effect of statins, sug-
protein prenylationgesting that the effect was indeed related to the inhibition
of the mevalonate pathway. Our results are quite similar Since both FPP and GGPP are used for the post-
translational modification of several cell proteins [18–to those reported regarding the effects of different statins
on VSMC proliferation [16]. It is likely that in both cases, 20], the above-presented data suggest that inhibition of
protein prenylation may be important in VSMC apopto-the hydrophilic properties of pravastatin prevented an
adequate access of the drug to the cytoplasm [17]. In sis. We have recently reported that HMG-CoA reductase
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A biochemical and morphological evaluation. Atherosclerosis 111:treatment was in fact associated with changes in the level
127–142, 1994
of prenylation of the protein p21 Rho-B [14], a protein 4. Massy ZA, Keane WF, Kasiske BL: Inhibition of the mevalonate
pathway: Benefits beyond cholesterol reduction? Lancet 347:102–that has been found to play an important role in apopto-
103, 1996sis [21–23]. Under normal conditions p21-Rho is an- 5. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than
chored into the cell membrane by its covalent binding just lower cholesterol. Lancet 348:1079–1082, 1996
6. Guijarro C, Egido J: Modulation of the mevalonate pathway:to either FPP or GGPP. When protein prenylation is
Potential mechanisms of vascular protection independent of cho-inhibited, Rho-B remains in the cytoplasm. The evalua- lesterol reduction. Cardiovascular Risk Factors 7:29–33, 1997
7. Ross R, Fuster V: The pathogenesis of atherosclerosis, in Athero-tion of the degree of presence of Rho B in the membrane
sclerosis and Coronary Artery Disease, edited by Fuster V, Rossor cytoplasmic compartments of the cell is therefore an
R, Topol EJ, Philadelphia, Lippincott-Raven, 1996, p 441
indirect assessment of its degree of prenylation. As 8. Guijarro C, Tun˜o´n J, Bustos C, Herna´ndez-Presa MA, Ortego
M, Egido J: La formacio´n de la placa aterosclerosa: Un procesoshown in Figure 2, treatment of rat VSMC with lipophilic
inflamatorio y fibroproliferativo. Clin Invest Arteriosclerosis 9:3–14,statins, but not pravastatin, was associated with an atten- 1997
uation of the presence of Rho B in the membrane, and 9. Hidaka Y, Eda T, Yonemoto M, Kamei T: Inhibition of cultured
vascular smooth muscle cell migration by simvastatin (MK-733).its appearance in the cytoplasmic fraction. Interestingly,
Atherosclerosis 95:87–94, 1992
the degree of inhibition of Rho B prenylation by differ- 10. Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR:
Inhibition of proliferation of arterial smooth-muscle cells by flu-ent statins closely parallels the pro-apoptotic effect of
vastatin. Lancet 348:1584, 1996statins (Figs. 1 and 2). Again, treatment with either meva- 11. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher
lonate, FPP or GGPP was associated with the disappear- K, Hughes A, Schachter M, Wolfe J, Sever P: Inhibition of
human vascular smooth muscle cell proliferation by lovastatin: Theance of Rho from the cytoplasm and its restoration into
role of isoprenoid intermediates of cholesterol synthesis. Eur J
the membrane fraction. Although Rho is an excellent Clin Invest 24:766–772, 1994
12. Rembold C: Could atherosclerosis originate from defective smoothcandidate to be involved in statin-induced apoptosis, our
muscle cell death (apoptosis)? Perspect Biol Med 39:405–408, 1996data cannot exclude that some other prenylated proteins 13. Bochaton Piallat ML, Gabbiani F, Redard M, Desmoulie`re A,
may play a similar or even greater role. Gabbiani G: Apoptosis participates in cellularity regulation during
rat aortic intimal thickening. Am J Pathol 146:1059–1064, 1995In summary, the present data demonstrate that lipo-
14. Guijarro C, Blanco-Colio LM, Ortego M, Ortiz A, Alonso C,
philic statins may induce the apoptosis of human VSMC. Plaza JJ, Dı´az C, Herna´ndez G, Egido J: 3-Hydroxy-3-methyl-
glutaryl coenzyme A reductase and isoprenylation inhibitors in-The potential role of statin-induced VSMC apoptosis in
duce apoptosis of vascular smooth muscle cells in culture. Circ Resthe evolution of atherosclerosis remains to be evaluated 83:490–500, 1998
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